Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice
AstraZeneca Nordic Balt, Sweden.
AstraZeneca Nordic Balt, Sweden.
Uppsala University, Sweden.
Uppsala University, Sweden.
Show others and affiliations
2017 (English)In: Primary Care Diabetes, ISSN 1751-9918, E-ISSN 1878-0210, Vol. 11, no 2, 184-192 p.Article in journal (Refereed) Published
Abstract [en]

Aims: To compare long-term changes in healthcare utilization and costs for type 2 diabetes patients before and after insulin initiation, as well as healthcare costs after insulin versus non-insulin anti-diabetic (NIAD) initiation. Methods: Patients newly initiated on insulin (n = 2823) were identified in primary health care records from 84 Swedish primary care centers, between 1999 to 2009. First, healthcare costs per patient were evaluated for primary care, hospitalizations and secondary outpatient care, before and up to seven years after insulin initiation. Second, patients prescribed insulin in second line were matched to patients prescribed NIAD in second line, and the healthcare costs of the matched groups were compared. Results: The total mean annual healthcare cost increased from 1656 per patient 2 years before insulin initiation to 3814 seven years after insulin initiation. The total cumulative mean healthcare cost per patient at year 5 after second-line treatment was 13,823 in the insulin group compared to 9989 in the NIAD group. Conclusions: Initiation of insulin in type 2 diabetes patients was followed by increased healthcare costs. The increases in costs were larger than those seen in a matched patient population initiated on NIAD treatment in second-line. (C) 2016 The Author(s). Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe. This is an open access article under the CC BY-NC-ND license.

Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2017. Vol. 11, no 2, 184-192 p.
Keyword [en]
Type 2 diabetes mellitus; Healthcare utilization; Healthcare costs; Observational study
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
URN: urn:nbn:se:liu:diva-136887DOI: 10.1016/j.pcd.2016.11.002ISI: 000396955300012PubMedID: 27894781OAI: oai:DiVA.org:liu-136887DiVA: diva2:1092065
Note

Funding Agencies|AstraZeneca

Available from: 2017-04-29 Created: 2017-04-29 Last updated: 2017-05-21

Open Access in DiVA

fulltext(1008 kB)25 downloads
File information
File name FULLTEXT01.pdfFile size 1008 kBChecksum SHA-512
b69507aa41be67e62a64d7274b9889449a3d43cfc659987da367595a03f1897eb06487011d36a5685da1c0e56e9ab5dbadeb96758ac255491412fd3f0231c621
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Östgren, Carl Johan
By organisation
Division of Community MedicineFaculty of Medicine and Health Sciences"Primary Health Care in Motala"
In the same journal
Primary Care Diabetes
Health Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar
Total: 25 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 100 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf